Linjeta FDA Approval Status

FDA Approved: No
Brand name: Linjeta
Generic name: human insulin [rDNA origin]
Dosage form: Injection
Previous Name: VIAject
Company: Biodel, Inc.
Treatment for: Diabetes, Type 1, Type 2 Diabetes

Linjeta (human insulin [rDNA origin]) is an investigational rapid-acting insulin analog intended for use in the treatment of type 1 and type 2 diabetes.

In November 2010, Biodel, Inc. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration requesting additional information regarding the company's new drug application (NDA) for Linjeta. The CRL stated the NDA could not be approved in its present form.

Development timeline for Linjeta

Date	Article
Nov  1, 2010	FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta
Mar  1, 2010	FDA Accepts VIAject NDA for Review
Jan  5, 2010	Biodel Submits VIAject New Drug Application to FDA for Treatment of Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer